AZD-7762 is a novel checkpoint kinase inhibitor with an IC50 of 5 and <10 nM for CHK1 and CHK2, respectively. AZD-7762 significantly prolonged the median time required for tumor volume doubling in response to gemcitabine and radiation. Together, findings suggest that G(2) checkpoint abrogation and homologous recombination repair inhibition both contribute to sensitization by Chk1 inhibition. Furthermore, they support the clinical use of AZD-7762 in combination with gemcitabine and radiation for patients with locally advanced pancreatic cancer.
ChemScene can order timely high quality and efficient services of various compounds from mg to kg level for some clients' bioscience research. We are committed to researching and developing reference compounds with high synthesis technology barriers and difficulties. ChemScene also has a tradition of working with scientists to bring new discoveries out of the laboratory and into the commercial arena.
View more >>
Description: AZD-8055 is a potent, selective, and orally bioavailable ATP-competitive mTOR kinase inhibitor with an IC50 of 0.8 nM. http://www.chemscene.com/AZD-8055.html